Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-gamma sign) algorithm

I. L. M. Reijers, A. M. Menzies, J. M. Versluis, P. Dimitriadis, M. Wouters, R. P. M. Saw, M. C. Klop, T. E. Pennington,W. Van Houdt, L. J. W. Bosch,S. Cornelissen, M. I. Lopez-Yurda, L. Grijpink-Ongering, R. Rawson,A. J. Spillane,R. A. Scolyer,B. van de Wiel,A. C. J. van Akkooi,G. V. Long, C. U. Blank

Annals of Oncology（2022）

引用 2|浏览5

暂无评分

关键词

stage iii melanoma patients,neoadjuvant domatinostat,nivolumab,relapse-free,interferon-gamma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要